Avisa is an earlyl stage company developing a transformative breath biomarker technology that rapidly detects certain pathogens and monitors medical therapy by detecting exhaled breath. Avisa’s technology platform covers a wide range of intellectual property around biomarkers that can detect bacterial lung infections in ten minutes including Healthcare Acquired Pneumonia, Ventilator Associated Pneumonia, Tuberculosis, Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.